Science News Roundup: Bristol-Myers reports positive data on cancer treatment acquired in Celgene dealReuters | Updated: 09-12-2019 02:30 IST | Created: 09-12-2019 02:26 IST
Following is a summary of current science news briefs. Bristol-Myers reports positive data on cancer treatment acquired in Celgene deal
Bristol-Myers Squibb Co on Saturday said that an experimental cancer therapy it acquired as part of its $74 billion deal for Celgene Corp produced positive results in a clinical trial. The company said it will apply for U.S. approval for the treatment for a type of advanced blood cancer by the end of the year. Half of the lymphoma patients alive three years after Gilead cell therapy treatment: study
Nearly half of lymphoma patients treated with Gilead Sciences Inc's Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to data presented on Saturday. Out of 101 patients treated with Yescarta for an aggressive blood cancer known as refractory large B-cell lymphoma in the study, 47 were still alive at least three years later, the data presented at the American Society of Hematology meeting in Orlando showed.